Exploratory evaluations of clinical outcomes by serostatus showed greater reduction in disease activity (SDAI and CDAI) in patients with RF/ACPA double-positive RA treated with first-line abatacept than in those receiving later-line therapy and those who had RF/ACPA double-negative RA. The gene discussed is PRTN3; the disease is rheumatoid arthritis.